434 related articles for article (PubMed ID: 32487241)
21. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
Veringa SJ; Biesmans D; van Vuurden DG; Jansen MH; Wedekind LE; Horsman I; Wesseling P; Vandertop WP; Noske DP; Kaspers GJ; Hulleman E
PLoS One; 2013; 8(4):e61512. PubMed ID: 23637844
[TBL] [Abstract][Full Text] [Related]
22. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.
Bellat V; Alcaina Y; Tung CH; Ting R; Michel AO; Souweidane M; Law B
Neuro Oncol; 2020 Oct; 22(10):1495-1504. PubMed ID: 32301996
[TBL] [Abstract][Full Text] [Related]
23. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
[TBL] [Abstract][Full Text] [Related]
24. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
Hollingworth MA; Zacharoulis S
J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
[TBL] [Abstract][Full Text] [Related]
25. Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Heravi Shargh V; Luckett J; Bouzinab K; Paisey S; Turyanska L; Singleton WGB; Lowis S; Gershkovich P; Bradshaw TD; Stevens MFG; Bienemann A; Coyle B
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35266-35280. PubMed ID: 34310112
[TBL] [Abstract][Full Text] [Related]
26. Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Smil D; Wong JF; Williams EP; Adamson RJ; Howarth A; McLeod DA; Mamai A; Kim S; Wilson BJ; Kiyota T; Aman A; Owen J; Poda G; Horiuchi KY; Kuznetsova E; Ma H; Hamblin JN; Cramp S; Roberts OG; Edwards AM; Uehling D; Al-Awar R; Bullock AN; O'Meara JA; Isaac MB
J Med Chem; 2020 Sep; 63(17):10061-10085. PubMed ID: 32787083
[TBL] [Abstract][Full Text] [Related]
27. Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.
Lian X; Kats D; Rasmussen S; Martin LR; Karki A; Keller C; Berlow NE
Acta Neuropathol Commun; 2021 May; 9(1):88. PubMed ID: 34001278
[TBL] [Abstract][Full Text] [Related]
28. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers.
Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H
J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054
[TBL] [Abstract][Full Text] [Related]
29. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
[TBL] [Abstract][Full Text] [Related]
30. Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.
Perrone MG; Ruggiero A; Centonze A; Carrieri A; Ferorelli S; Scilimati A
Curr Med Chem; 2021; 28(17):3287-3317. PubMed ID: 32767913
[TBL] [Abstract][Full Text] [Related]
31. DIPG in Children - What Can We Learn from the Past?
Vanan MI; Eisenstat DD
Front Oncol; 2015; 5():237. PubMed ID: 26557503
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Shi S; Lu S; Jing X; Liao J; Li Q
World Neurosurg; 2021 Apr; 148():e565-e571. PubMed ID: 33476781
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy.
Szychot E; Walker D; Collins P; Hyare H; Shankar A; Bienemann A; Hollingworth M; Gill S
Int J Clin Oncol; 2021 Apr; 26(4):647-658. PubMed ID: 33575829
[TBL] [Abstract][Full Text] [Related]
34. Real-Time, in Vivo Correlation of Molecular Structure with Drug Distribution in the Brain Striatum Following Convection Enhanced Delivery.
Tosi U; Kommidi H; Bellat V; Marnell CS; Guo H; Adeuyan O; Schweitzer ME; Chen N; Su T; Zhang G; Maachani UB; Pisapia DJ; Law B; Souweidane MM; Ting R
ACS Chem Neurosci; 2019 May; 10(5):2287-2298. PubMed ID: 30838861
[TBL] [Abstract][Full Text] [Related]
35. Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
Sasaki T; Katagi H; Goldman S; Becher OJ; Hashizume R
Neurosurgery; 2020 Nov; 87(6):E680-E688. PubMed ID: 32674144
[TBL] [Abstract][Full Text] [Related]
36. The intersect of neurosurgery with diffuse intrinsic pontine glioma.
Kuzan-Fischer CM; Souweidane MM
J Neurosurg Pediatr; 2019 Dec; 24(6):611-621. PubMed ID: 31786541
[TBL] [Abstract][Full Text] [Related]
37. MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model.
Martinez P; Nault G; Steiner J; Wempe MF; Pierce A; Brunt B; Slade M; Song JJ; Mongin A; Song KH; Ellens N; Serkova N; Green AL; Borden M
Neurooncol Adv; 2023; 5(1):vdad111. PubMed ID: 37795179
[TBL] [Abstract][Full Text] [Related]
38. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin and [Pt(R,R-DACH)(panobinostat
Boulet MHC; Marsh LK; Howarth A; Woolman A; Farrer NJ
Dalton Trans; 2020 May; 49(17):5703-5710. PubMed ID: 32297619
[TBL] [Abstract][Full Text] [Related]
40. Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors.
Wu H; Lu H; Xiao W; Yang J; Du H; Shen Y; Qu H; Jia B; Manna SK; Ramachandran M; Xue X; Ma Z; Xu X; Wang Z; He Y; Lam KS; Zawadzki RJ; Li Y; Lin TY
Adv Mater; 2020 Apr; 32(14):e1903759. PubMed ID: 32078198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
